CDKN2C
History
| Entity | Tier | Description |
|---|---|---|
 |
2 | relevance in BL not firmly established |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 2.54 |
| BL | Thomas cohort | 3.40 |
| BL | Panea cohort | 3.00 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | No | No | 16.525 | 50.872 |
| DLBCL | No | No | 3.474 | 0.000 |
| FL | No | No | 0.000 | 0.000 |
[!NOTE] First described in BL in 2023 by Thomas N
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
## CDKN2C
Expression 
## References 1. Thomas N,
Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, Barta S,
Bartlett NL, Bethony J, Bhatia K, Bowen J, Bryan AC, Cesarman E, Casper
C, Chadburn A, Cruz M, Dittmer DP, Dyer MA, Farinha P, Gastier-Foster
JM, Gerrie AS, Grande BM, Greiner T, Griner NB, Gross TG, Harris NL,
Irvin JD, Jaffe ES, Henry D, Huppi R, Leal FE, Lee MS, Martin JP, Martin
MR, Mbulaiteye SM, Mitsuyasu R, Morris V, Mullighan CG, Mungall AJ,
Mungall K, Mutyaba I, Nokta M, Namirembe C, Noy A, Ogwang MD, Omoding A,
Orem J, Ott G, Petrello H, Pittaluga S, Phelan JD, Ramos JC, Ratner L,
Reynolds SJ, Rubinstein PG, Sissolak G, Slack G, Soudi S, Swerdlow SH,
Traverse-Glehen A, Wilson WH, Wong J, Yarchoan R, ZenKlusen JC, Marra
MA, Staudt LM, Scott DW, Morin RD. Genetic subgroups inform on
pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023 Feb
23;141(8):904–916.
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
